Methotrexate (MTX) is an anti-rheumatic drug and is administered to patients with autoimmune diseases, particularly rheumatoid arthritis (RA). MTX suppresses the hyperimmune state of RA patients and has an excellent inhibitory effect regarding articular destruction. Therefore, MTX is currently used as first-line anchor drug for RA therapy. 1, 2 However, an immunosupperessive state induced by MTX contributes to development of various types of lymphoproliferative disorders, including Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU). [3] [4] [5] EBVMCU was first reported by Dojcinov et al. in 2010, 6 and newly categorized as a provisional entity in the 2017 World Health Organization (WHO) classification. 7 The disease occurs in elderly or iatrogenic immunocompromised patients and presents as a well-defined and isolated lesion involving the skin, oral cavity, or gastrointestinal tract. EBVMCU may affect regional lymph nodes, however, there is no evidence of systemic involvement. Usually, EBVMCU follows an indolent and self-limited course. It is characterized by spontaneous regression or complete remission upon reduction of immunosuppression. In total, 28 cases of MTX-associated EBVMCU (MTX-EBVMCU), mostly arising in RA patients, have been reported thus far. 6, [8] [9] [10] [11] [12] Although clinical and pathological characteristics of the disease have been gradually highlighted, some of its aspects remain to be elucidated. Particularly, clinical behavior of RA and treatment for RA after MTX cessation have not been well described. Herein, we report nine cases of MTX-EBVMCU with clinical information regarding RA.
MATERIALS AND METHODS

Patient samples
A total of 41 cases of MTX-associated lymphoproliferative disorder (MTX-LPD) diagnosed between 2006 and 2017 were retrieved from the medical files at Aichi Medical University Hospital. We defined MTX-LPD as LPD arising in patients who had been receiving MTX at the time of diagnosis. The MTX-LPD cases were diagnosed as follows according to the 2017 WHO classification using morphology and immunophenotyping: diffuse large B-cell lymphoma (DLBCL) (n ¼ 23), EBVMCU (n ¼ 9), Hodgkin lymphoma (HL) (n ¼ 4), polymorphic LPD (n ¼ 3), HL-like LPD (n ¼ 1), and Tcell lymphoma (n ¼ 1). The nine cases of EBVMCU were retrospectively investigated for this study. All cases were independently reviewed by two pathologists (authors A.S. and E.T.) to confirm the diagnosis and immunophenotype. No cases were positive for human T-lymphotropic virus-1 and human immunodeficiency virus (HIV) antibody in sera. Clinical and laboratory data of the patients along with the follow-up data were obtained from the medical records of Aichi Medical University Hospital. Involved sites were usually examined on biopsy or by radiographic evaluation, such as computed tomography and positron emission tomography. The institutional review board of Aichi Medical University Hospital approved the study protocol.
Evaluation of activity of RA
The activity of RA was evaluated according to the 28-joint disease activity score (DAS28-CRP). DAS28-CRP was calculated by the following formula: DAS28-CRP ¼ 0.56
RA activity of the patients was divided into high (>4.1), moderate (2.7-4.1), low disease activity (<2.7), and clinical remission (<2.3) based on DAS28-CRP. 13 
Histological and immunohistochemical staining
Tissue samples were fixed in 10% formalin and embedded in paraffin, followed by staining with hematoxylin and eosin of 4 mm-thick sections. Immunoperoxidase studies were performed on formalin-fixed paraffin-embedded sections. Monoclonal antibodies used were anti-CD10 (Novocastra Laboratories, Newcastle, UK), L26/CD20, CD30, BCL-6 (DAKO, Santa Fe, CA, USA), CD15 (Nichirei, Tokyo, Japan) MUM-1 (Santa Cruz Biotechnologies, Dallas, TX, USA) and PD-L1 (SP142 and E1J2J; Spring Bioscience, Pleasanton, CA, USA). All antibodies were used after antigen retrieval after being heated in a microwave oven.
In situ hybridization study
The presence of EBV small ribonucleic acid was examined by in situ hybridization using EBV-encoded small nuclear early region (EBER) oligonucleotides on formalin-fixed, paraffin-embedded sections as described previously.
14 IgH PCR study DNA was extracted from formalin-fixed tissues, and PCR analysis of the IgH gene was conducted using the BI-OMED2 protocol, as described elsewhere. 15 
RESULTS
Clinical features and outcome
The clinical features and outcome of the nine patients (four men, five women) are summarized in Table 1 . Two patients (case 1 and 9) had cervical lymphadenopathy, however, they showed no evidence of systemic involvement. After the diagnosis of EBVMCU, MTX and other IS (TNFa inhibitor and TAC) were immediately withdrawn in all patients. Seven patients showed spontaneous regression (SR) after withdrawal of IS. The other two patients (case 1 and 3) did not show SR within 4 weeks, and received cytotoxic chemotherapy; R-CHOP (combination of rituximab, cyclophosphamide, vincristine, adriamycin and prednisolone) (case 1), ABVD (combination of adriamycin, bleomycin, vinblastine, and dacarbazine) (case 3). Eventually, all achieved complete remission (CR). None of the patients experienced relapse of the disease. Table 2 and Figure 2 summarize the histological, immunohistochemical and molecular features of the nine cases. Histologically, all the cases had well-circumscribed mucosal ulcer accompanied by necrosis. The underlying infiltrate comprised of intermediate to large atypical lymphoid cells with polymorphous proliferation including small lymphocytes, histiocytes, and eosinophils. Bizarre giant cells with Hodgkin and Reed-Sternberg-like (H/RS-like) appearance were present in variable numbers in all cases. Case 3 contained an area that was rich in H/RS-like cells with CD15 expression. Therefore, the lesion was considered to have characteristics of HL, and ABVD therapy, a standard therapy for HL, was administered to the patient. 
Histological, immunohistochemical and molecular features
ND, not done; Poly, polymorphous; UD, undetectable Immunohistochemically, all nine cases were positive for CD20, MUM1, and EBER. Most of the cases (8/9) expressed CD30, whereas only one of eight cases showed positivity for CD15. PD-L1 expression was assessed by two clones, SP142 and E1J2J, for seven cases. All seven cases were negative for PD-L1. EBV latency status was evaluated for eight cases. Seven of eight were positive for LMP1 and negative for EBNA2, indicating type II latency of EBV. One case (case 4) showed negativity for both LMP1 and EBNA2, indicating type I latency.
IgH PCR analysis was successful in five cases. A clonal IgH rearrangement was detected in three (60%) cases.
Clinical features regarding RA
The clinical features regarding RA are summarized in Table 3 . At the time of diagnosis of EBVMCU, according to the DAS28-CRP, RA activity of the patients were categorized as moderate (n ¼ 6), low (n ¼ 1), and clinical remission (n ¼ 2). Most of the patients suffered from exacerbation of RA with polyarticular inflammation after about 2 months from withdrawal of IS. Indeed, eight patients in our series had RA flare (acute episodes of pain and inflammation) and received therapy to control the RA activity. Rituximab (R) was administered to three patients; case 1, 2 and case 5. Only R was used for case 1 after R-CHOP therapy. Case 2 first received R and, 15 months later, abatacept was added to the therapy. Case 5 received R monotherapy. The three patients had received 375 mg/m 2 of R in three months as one cycle, and five cycles of R injection were performed in total. The remaining four patients were treated by other biological agents (abatacept and TNFa inhibitors), PSL, or conventional systemic disease-modifying anti-rheumatic-drugs. Regarding the RA activity, all were in the status of low disease activity or clinical remission. 6, [8] [9] [10] [11] [12] Of the 28 cases, clinical information was available in 26 cases; 24 of them showed spontaneous regression after withdrawal of MTX, and the other two cases required R-CHOP therapy to acquire CR. In our series, two patients did not show SR, and received systemic chemotherapy, R-CHOP and ABVD. Chemotherapy was administered to our two cases after the 4 week observation following the IS cessation. It is now widely accepted that discontinuation of IS is the initial treatment for MTX-LPD patients, and 23-70% of the patients showed SR in previous reports. 4, 8, [19] [20] [21] [22] If not, additional treatment is needed. However, there is no consensus about appropriate length of observation after withdrawal of IS. Rizzi et al. found that CR mostly occurred within 4 weeks after IS cessation. 23 On the other hand, a number of the MTX-associated EBVMCU cases took more than 2 months to achieve CR after withdrawal of IS. 8, 12 Furthermore, none of these cases had relapse of the EBVMCU. Taken together, regarding the two cases of our series, we could observe for a longer period to avoid systemic chemotherapy. Very recently, Saito et al. reported that lymphocyte recovery after MTX cessation was significantly higher in MTX-LPD cases that showed SR, compared with cases that did not. 22 Tracking lymphocyte count after IS cessation might be a good indicator to predict SR in MTX-associated EBVMCU patients. EBVMCU is associated with various types of immunosuppression. The immunodeficient status of the patient was caused by immunosenescence due to aging, HIV infection, chemotherapy or a variety of IS. The function of EBV-specific cytotoxic T lymphocytes, which regulate EBV-positive cell proliferation, is suppressed in the patient. This dysregulation in the immune surveillance for EBV was assumed to result in the emergence of the EBVMCU. 24 Feng et al. reported, in contrast to other causes of immunodeficiency, MTX may directly reactivate latent EBV of the patients. Therefore, we think that the MTX might induce EBVMCU in RA patients by immunosuppression as well as by reactivating latent EBV. 25 Besides, considering the age of our cases, median 75 years (range, 48-84 years), age-related immunosenescence might be partly associated with development of EBVMCU.
In five cases of our series, TNFa inhibitors or TAC were used as IS in addition to MTX for RA treatment. For that reason, these IS might also play a role in pathogenesis of EBVMCU. However, Wolfe et al. reported that TNFa inhibitors have not increased the risk of LPD in RA patients. 26 In addition, only one case of EBVMCU arising in an RA patient without MTX administration who had been treated with azathioprine has reported so far. 6 Thus, we consider that MTX contributes to the EBVMCU genesis in RA patients. The PD1/PD-L1 pathway is important for immune evasion of tumor cells that contribute to lymphomagenesis through T-cell exhaustion. 27 In previous reports, PD-L1 expression of tumor cells was detected in the majority of EBV-positive (EBV þ ) HL and 16 to 100% of EBV-positive DLBCL-NOS. [28] [29] [30] It is speculated that immune evasion of tumor cells through the PD1/PD-L1 pathway is key for the pathogenesis of these EBV þ lymphomas. Morphologically and immunohistochemically, EBVMCU shows an overlap with EBV þ HL and DLBCL-NOS. Therefore, we speculated immune evasion may also play a key role in the development of EBVMCU. We assessed the PD-L1 expression of the tumor cells by two different clones, SP142 and E1J2J, because some reports showed the interchangeability of positivity among separate clones. 31, 32 The difference of antibody reactivity is partly caused by truncation of 3'-untranslated PD-L1 gene. The truncation makes PD-L1 undetectable by antibodies except for E1J2J, which recognize the N-terminus of PD-L1. 33 In the present study, all of the cases tested showed negativity for both clones. This immunohistochemical data may support the assertion that immunodeficiency but not immune evasion is the main cause of MTX-EBVMCU. According to previous reports, high disease activity of RA, high LDH level and accumulative MTX dose were suggested as risk factors for MTX-LPD. 34, 35 In the present cases, none were categorized as having severe activity of RA, and only four cases showed mild elevation of LDH. Regarding the accumulative MTX dose, duration from start of MTX to onset of EBVMCU and MTX dose varied widely between the patients. Therefore, we could not point out any clinical feature that might be related to occurrence of MTXassociated EBVMCU. However, the previous reports did not include EBVMCU cases in their MTX-LPD series. Therefore, further research in larger series including EBVMCU is needed to clarify this issue. Treatment for RA becomes difficult when MTX-LPD including EBVMCU arises in the patients. After the withdrawal of IS, the majority of patients experience RA flare. Actually, RA treatment after the regression of the LPD has still not been well established. Usually, reintroduction of MTX is avoided to prevent a relapse of LPD. R is commonly used for RA patients who show impaired response to other biologicals such as TNF-a inhibitors. 36 Furthermore, major guidelines and recommendations suggested that R is more preferable than anti-TNF agents for RA treatment after the regression of the LPD. 1, 2, 37 Furthermore, R might be effective to prevent regrowth of EBVMCU. In our series, all three patients who received R for the management of RA flare showed good clinical course. All were in the status of clinical remission for RA, and none of them experienced EBVMCU relapse. Therefore, we suggest that R is the preferable agent for RA treatment after the regression of the MTX-associated EBVMCU.
In summary, MTX-associated EBVMCU has an indolent clinical course and spontaneous regression after cessation of IS can be expected. In addition to immunodeficiency due to MTX, age-related immunosenescence might partly contribute to development of EBVMCU. After the withdrawal of MTX, the majority of patients experience RA flare and treatment is needed. In our series, RA was well controlled without reinitiating MTX. Therefore, to prevent the relapse of EBVMCU, it might be better to avoid MTX reintroduction after the patients acquire CR, and R might be the more preferable agent for RA treatment. Further analysis in larger series will certainly increase our understanding of MTXassociated EBVMCU.
